“A Game-Changer” HER2 TKI for NSCLC

The investigational HER2-selective tyrosine kinase inhibitor zongertinib appears remarkably effective in patients with HER2-mutant non–small cell lung cancer. Robust, durable responses were seen in the Beamion LUNG-1 trial and side effects were minimal due to the drug’s improved specificity for HER2 over EGFR.